Stoke Therapeutics, Inc. (Nasdaq: STOK) has announced the pricing of its upsized underwritten public offering of common stock, aiming to raise $125 million. The company will offer 5,555,557 shares of its common stock at $13.50 per share, alongside pre-funded warrants to purchase up to 3,703,730 shares of its common stock. J.P. Morgan Securities LLC is acting as the sole book-running manager for the offering. The proceeds will be used to fund research, clinical development, manufacturing, and general corporate purposes. The offering is expected to close in early April, subject to customary conditions. Stoke Therapeutics is known for its innovative approach to addressing severe diseases through RNA-based medicines.
Stoke Therapeutics Prices Upsized Public Offering at $13.50 Per Share
Date:
Updated: [falahcoin_post_modified_date]
More like thisRelated
Revolutionary Small Business Exchange Network Connects Sellers and Buyers
Revolutionary SBEN connects small business sellers and buyers, transforming the way businesses are bought and sold in the U.S.
District 1 Commissioner Race Results Delayed by Recounts & Ballot Reviews, US
District 1 Commissioner Race in Orange County faces delays with recounts and ballot reviews. Find out who will come out on top in this close election.
Fed Minutes Hint at Potential Rate Cut in September amid Economic Uncertainty, US
Federal Reserve minutes suggest potential rate cut in September amid economic uncertainty. Find out more about the upcoming policy decisions.
Baltimore Orioles Host First-Ever ‘Faith Night’ with Players Sharing Testimonies, US
Experience the powerful testimonies of Baltimore Orioles players on their first-ever 'Faith Night.' Hear how their faith impacts their lives on and off the field.
